Matches in Nanopublications for { ?s ?p "[Furthermore, the use of the FDA-approved drug trifluoperazine hydrochloride (TFP), which has been shown to inhibit FOXO1 nuclear export, restored sensitivity to AKT-driven erlotinib resistance through modulation of the KLF6/FOXO1 signaling cascade in both cell culture and xenograft models of lung adenocarcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 11 of
11
with 100 items per page.
- assertion description "[Furthermore, the use of the FDA-approved drug trifluoperazine hydrochloride (TFP), which has been shown to inhibit FOXO1 nuclear export, restored sensitivity to AKT-driven erlotinib resistance through modulation of the KLF6/FOXO1 signaling cascade in both cell culture and xenograft models of lung adenocarcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP424909.RADLddkRZi2VOU3dW1mnB77DWxBq2HWxRROJH31HOnjng130_assertion description "[Furthermore, the use of the FDA-approved drug trifluoperazine hydrochloride (TFP), which has been shown to inhibit FOXO1 nuclear export, restored sensitivity to AKT-driven erlotinib resistance through modulation of the KLF6/FOXO1 signaling cascade in both cell culture and xenograft models of lung adenocarcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP424909.RADLddkRZi2VOU3dW1mnB77DWxBq2HWxRROJH31HOnjng130_provenance.
- NP782659.RAnjP_YhS5Yzk_UT4GJFdyYEhmVKae1w_mxv0eO5AiUBk130_assertion description "[Furthermore, the use of the FDA-approved drug trifluoperazine hydrochloride (TFP), which has been shown to inhibit FOXO1 nuclear export, restored sensitivity to AKT-driven erlotinib resistance through modulation of the KLF6/FOXO1 signaling cascade in both cell culture and xenograft models of lung adenocarcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP782659.RAnjP_YhS5Yzk_UT4GJFdyYEhmVKae1w_mxv0eO5AiUBk130_provenance.
- assertion description "[Furthermore, the use of the FDA-approved drug trifluoperazine hydrochloride (TFP), which has been shown to inhibit FOXO1 nuclear export, restored sensitivity to AKT-driven erlotinib resistance through modulation of the KLF6/FOXO1 signaling cascade in both cell culture and xenograft models of lung adenocarcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP296158.RAw1QIZLHX4TkJQrJUofAFf9Zarift_5HIwbXt1WZsk7E130_assertion description "[Furthermore, the use of the FDA-approved drug trifluoperazine hydrochloride (TFP), which has been shown to inhibit FOXO1 nuclear export, restored sensitivity to AKT-driven erlotinib resistance through modulation of the KLF6/FOXO1 signaling cascade in both cell culture and xenograft models of lung adenocarcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP296158.RAw1QIZLHX4TkJQrJUofAFf9Zarift_5HIwbXt1WZsk7E130_provenance.
- assertion description "[Furthermore, the use of the FDA-approved drug trifluoperazine hydrochloride (TFP), which has been shown to inhibit FOXO1 nuclear export, restored sensitivity to AKT-driven erlotinib resistance through modulation of the KLF6/FOXO1 signaling cascade in both cell culture and xenograft models of lung adenocarcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP322452.RAWRrtmJmvlnwiKP44WFJ9-CqgSRzABUjQUi5OgySrWJ8130_assertion description "[Furthermore, the use of the FDA-approved drug trifluoperazine hydrochloride (TFP), which has been shown to inhibit FOXO1 nuclear export, restored sensitivity to AKT-driven erlotinib resistance through modulation of the KLF6/FOXO1 signaling cascade in both cell culture and xenograft models of lung adenocarcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP322452.RAWRrtmJmvlnwiKP44WFJ9-CqgSRzABUjQUi5OgySrWJ8130_provenance.
- NP860363.RAypa77h26BwAKGLwSk_dpH2c_cZc-Q0_NCGOQSqfgh0s130_assertion description "[Furthermore, the use of the FDA-approved drug trifluoperazine hydrochloride (TFP), which has been shown to inhibit FOXO1 nuclear export, restored sensitivity to AKT-driven erlotinib resistance through modulation of the KLF6/FOXO1 signaling cascade in both cell culture and xenograft models of lung adenocarcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP860363.RAypa77h26BwAKGLwSk_dpH2c_cZc-Q0_NCGOQSqfgh0s130_provenance.
- NP405450.RAmuCha19MLC2-B3XCEqAXUeEA_eiXJxmbvV23R1MwkRI130_assertion description "[Furthermore, the use of the FDA-approved drug trifluoperazine hydrochloride (TFP), which has been shown to inhibit FOXO1 nuclear export, restored sensitivity to AKT-driven erlotinib resistance through modulation of the KLF6/FOXO1 signaling cascade in both cell culture and xenograft models of lung adenocarcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP405450.RAmuCha19MLC2-B3XCEqAXUeEA_eiXJxmbvV23R1MwkRI130_provenance.
- NP986327.RAAIIdi7mjgwL2y9puBU6Y23q8PvtBtAWb7JZXArSEOzc130_assertion description "[Furthermore, the use of the FDA-approved drug trifluoperazine hydrochloride (TFP), which has been shown to inhibit FOXO1 nuclear export, restored sensitivity to AKT-driven erlotinib resistance through modulation of the KLF6/FOXO1 signaling cascade in both cell culture and xenograft models of lung adenocarcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP986327.RAAIIdi7mjgwL2y9puBU6Y23q8PvtBtAWb7JZXArSEOzc130_provenance.
- NP986325.RAzvEvmoadF-1jW35-cwn1dpIjRV_oInJDB9P_i8hVLcE130_assertion description "[Furthermore, the use of the FDA-approved drug trifluoperazine hydrochloride (TFP), which has been shown to inhibit FOXO1 nuclear export, restored sensitivity to AKT-driven erlotinib resistance through modulation of the KLF6/FOXO1 signaling cascade in both cell culture and xenograft models of lung adenocarcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP986325.RAzvEvmoadF-1jW35-cwn1dpIjRV_oInJDB9P_i8hVLcE130_provenance.